Clinical trials for Attention deficit hyperactivity disorder (ADHD)

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Attention deficit hyperactivity disorder (ADHD). For all clinical trials, go to clinical trials search

This list shows clinical trials for Attention deficit hyperactivity disorder (ADHD)

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Attention deficit hyperactivity disorder (ADHD)
Title Recruitment status Location
Clinical Trial of Concerta for the treatment of ADHD in adult offenders Authorised United Kingdom
A study to look at SPD489 in children and adolescents with ADHD Authorised United Kingdom
Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder Authorised United Kingdom
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Treatment-Naïve Children and Adolescents. (ADHD-LIFE Study) - (ADHD-LIFE Study) Authorised United Kingdom
Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Treatment-Naïve Children and Adolescents. Authorised United Kingdom
Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study Authorised United Kingdom
A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD) Estudio de fase 4, abierto, multicéntrico, de la seguridad durante 2 años de tratamiento con lisdexanfetamina dimesilato en niños y adolescentes de 6 a 17 años con trastorno por déficit de atención con hiperactividad (TDAH) Authorised United Kingdom
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD) Authorised United Kingdom
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Treatment-Naïve Children and Adolescents. (ADHD-LIFE Study) - (ADHD-LIFE Study) Authorised United Kingdom
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder. - Lamda 2 Authorised United Kingdom

Page last reviewed: 25/04/2016

Next review due: 01/04/2019